Lightspeed Microscopy, Inc., a Seattle, WA-based end-to-end 3D pathology platform, raised $4m in Series A financing.
The round – expected to close with participation from additional investors by mid-July – was led by Dynamk Capital.
The company intends to use the funds to commercialize and scale its microscopy platform.
Led by Nicholas Reder, MD, MPH, CEO, Lightspeed has developed technology that combines novel chemistry, patented open-top light-sheet microscopy, and cloud-based AI data analysis to non-destructively image large tissues in 3D at a sub-cellular resolution. The solution includes tissue labelling, tissue clearing, high-throughput imaging, cloud-based processing, and 3D digital analysis.
Lightspeed was spun-out of the University of Washington.